Director Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)

In this article:

Director Thomas Krummel has sold 20,000 shares of PROCEPT BioRobotics Corp (NASDAQ:PRCT), according to a recent SEC Filing dated 2024-03-04. The transaction was executed at a stock price of $48.53 per share, which places the total value of the shares sold at approximately $970,600.PROCEPT BioRobotics Corp is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company's proprietary technology is designed to enhance the quality of life for patients suffering from debilitating urological conditions.Over the past year, the insider, Thomas Krummel, has engaged in the sale of 20,000 shares and has not made any purchases of the company's stock. The recent transaction is part of a series of insider activities at PROCEPT BioRobotics Corp, which has seen a total of 16 insider sells and no insider buys over the past year.

Director Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)
Director Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)

The market capitalization of PROCEPT BioRobotics Corp stands at $2.406 billion, based on the stock's trading price on the day of the insider's transaction.For more detailed information on insider transactions and the company's financial performance, investors and analysts are encouraged to visit the official SEC website and review the filed documents.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.

Advertisement